Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 27Prostatic Hyperplasia 3Neoplasms 3Urinary Bladder Neoplasms 1Recurrence 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Lower Urinary Tract Symptoms 1Erectile Dysfunction 1Adenocarcinoma of the Prostate 1

Interventions

enzalutamide 2sipuleucel-T 1pazopanib 1capivasertib 1Watchful Waiting 1STA 9090 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Dutasteride 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma of the Prostate × Dutasteride × Clear all
NCT01368003 2015-09-01

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡